Several advocacy groups are focusing their efforts on reimbursement issues that they believe threaten patients’ access to care.
A high-cost therapy coupled with a complex and evolving reimbursement model has created what some are calling a healthcare crisis for tens of thousands of chronically ill patients.
Some commonly held misunderstandings about reimbursement are clarified, including reimbursement for IVIG, SCIG, affordability and assistance.
Clearing up common misunderstandings about reimbursement rates for subcutaneous immune globulin therapy and vaccine costs.
Modifications in the steps and ingredients of the manufacturing process of immune globulin have changed the world of immune therapy.
The healthcare reform laws include new strict reporting guidelines for the medical industry, and physicians need to ensure that what is reported is correct to protect their practice.
The FDA’s new strategy to ensure that the safety of certain drugs outweighs the risks they potentially pose to patients continues to evolve as the healthcare industry takes an active role in current and future REMS requirements.
Examining issues regarding SCIG billing, coding and Medicare claims, along with questions about certification of homebound patients and products with new reimbursement codes.
With the push to reduce the cost of healthcare yet improve the quality and efficiency of care, Accountable Care Organizations could be a solution.
We're answering questions about switching from intravenous immune globulin therapy to subcutaneous immune globulin therapy, copayment for self-injectables, the definition of homebound patients and more.
Discussing reimbursement codes and insurance coverage of Fluzone and off-label uses for Rituxan.